Therapy Areas: Cardiovascular
Lonza signs strategic collaboration with DiNAQOR
28 November 2019 -

Switzerland-based Lonza has signed a strategic collaboration with DiNAQOR AG, a global gene therapy platform company.

It was reported yesterday that the collaboration is aimed at advancing DiNAQOR's preclinical programs intended for the treatment of cardiac myosin-binding protein-C cardiomyopathies (MYBPC3), a genetic condition that can result in heart failure.

According to the terms of the collaboration, Lonza will provide DiNAQOR with preclinical, clinical and commercial production support for the company's lead preclinical program DiNA-001, an adeno-associated virus (AAV) gene therapy program for patients with MYBPC3-linked cardiomyopathy. Lonza's state-of-the-art cell-and-gene-therapy manufacturing facility in Houston, Texas is to manage all product supply for DiNA-001. Through this collaboration, DiNAQOR will be able to leverage Lonza's extensive, dedicated teams and laboratories for viral-vector process-development, located in Houston.



Related Headlines